Actuate Therapeutics appoints former Mersana CEO Martin Huber to board

ACTUATE THERAPEUTICS, INC.

Board expanded from 7 to 8; Huber appointed as Class III director effective May 1, 2026.
Huber previously President/CEO of Mersana until Jan 2026 acquisition by Day One Biopharmaceuticals.
Receives initial option grant of 30,000 shares (3-year vest), annual retainer $44,000, plus $3,000/quarter consulting fee.
He will serve on Nominating and Corporate Governance Committee; expertise includes approvals of pembrolizumab, niraparib, others.
Company highlights his role in advancing elraglusib for difficult-to-treat cancers including metastatic pancreatic cancer.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Martin H. Huber

Class III Director

ACTU · ACTUATE THERAPEUTICS, INC.

Effective: 2026-05-01
Filed: May 6, 2026, 7:59 PM ET

On May 1, 2026, the Board of Directors ("Board") of Actuate Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin H. Huber was appointed as Class III Director at ACTUATE THERAPEUTICS, INC..

Action: appointed
Role: Class III Director

Exact text from the filing

On May 1, 2026, the Board of Directors ("Board") of Actuate Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.

View on SEC.gov

ACTUATE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001683168-26-003515

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.